| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Modotuximab (anti-EGFR)
CAS:1310460-86-6
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K14068
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Modotuximab
CAS:1310460-86-6
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Modotuximab
CAS:1310460-86-6
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Zatuximab
CAS:1310460-86-6
Purity:>95% Package:100ug;200ug;1mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Modotuximab
CAS:1310460-86-6
Purity:95% Package:1mg/RMB 2480;5mg/RMB 7460;10mg/RMB 9860
|
|
| | Modotuximab Basic information |
| Product Name: | Modotuximab | | Synonyms: | Modotuximab;Zatuximab;Research Grade Modotuximab (DHB86904);Research Grade Zatuximab (DHB86910);Research Grade Modotuximab;Research Grade Zatuximab;Modotuximab (anti-EGFR) | | CAS: | 1310460-86-6 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Modotuximab Structure]() |
| | Modotuximab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Modotuximab Usage And Synthesis |
| Uses | Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo[1]. | | References | [1] Keir
ST, et al. Sym004-induced EGFR
elimination is associated with profound anti-tumor activity in EGFRvIII
patient-derived glioblastoma models. J Neurooncol. 2018 Jul;138(3):489-498. DOI:10.1007/s11060-018-2832-6
[2] Modotuximab. IMGT Database. |
| | Modotuximab Preparation Products And Raw materials |
|